Literature DB >> 15970763

Social implications of hyperdynamic facial lines and patient satisfaction outcomes.

Sue Ellen Cox1, J Charles Finn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15970763     DOI： 10.1097/01.iio.0000167237.49396.7b

Source DB:  PubMed          Journal:  Int Ophthalmol Clin        ISSN： 0020-8167


× No keyword cloud information.
  12 in total

1.  [The satisfied patient in aesthetic dermatology. Consensus work on patient satisfaction in botulinum toxin A treatment].

Authors:  O P Kreyden; B Rzany; P Becker-Wegerich; C Boudny-Frey; P Carrozza-Merlani; M Hess-Schmid; B Schlagenhauff
Journal:  Hautarzt       Date:  2015-02       Impact factor: 0.751

2.  IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations.

Authors:  Yana Yutskovskaya; Elena Gubanova; Irina Khrustaleva; Vasiliy Atamanov; Anastasiya Saybel; Elena Parsagashvili; Irina Dmitrieva; Elena Sanchez; Natalia Lapatina; Tatiana Korolkova; Alena Saromytskaya; Elena Goltsova; Elmira Satardinova
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-06-05

3.  Safety and Effectiveness of Juvéderm Ultra Plus Injectable Gel in Correcting Severe Nasolabial Folds in Chinese Subjects.

Authors:  Dong Li; Yun Xie; Qin Li; Jiaming Sun; Ping Jiang; Yi Jia; Diane K Murphy; Qingfeng Li
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-01-16

4.  Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial.

Authors:  Benjamin Ascher; Berthold Rzany; Philippe Kestemont; Said Hilton; Marc Heckmann; Isaac Bodokh; Ernst Magnus Noah; Dominique Boineau; Martina Kerscher; Magali Volteau; Philippe Le Berre; Philippe Picaut
Journal:  Aesthet Surg J       Date:  2020-08-14       Impact factor: 4.283

5.  Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study.

Authors:  Elena Gubanova; May Haddad Tabet; Yvonne Bergerova; Olena Moiseieva; Andrey Chemeris; Elena Sanches; Alisa Sharova; Luisa Rodriguez Pose; Romain Raymond; Inna Prygova; Ian Carlisle
Journal:  Aesthetic Plast Surg       Date:  2018-08-17       Impact factor: 2.326

6.  One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA.

Authors:  Carla de Sanctis Pecora
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-02-05

7.  Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.

Authors:  Benjamin Ascher; Berthold Rzany; Philippe Kestemont; Said Hilton; Marc Heckmann; Isaac Bodokh; Ernst Magnus Noah; Dominique Boineau; Martina Kerscher; Magali Volteau; Philippe Le Berre; Philippe Picaut
Journal:  Aesthet Surg J       Date:  2020-01-01       Impact factor: 4.283

8.  The Psychological Impacts of Upper Facial Lines: A Qualitative, Patient-Centered Study.

Authors:  Steven Dayan; Steven G Yoelin; Koenraad De Boulle; Julie K Garcia
Journal:  Aesthet Surg J Open Forum       Date:  2019-05-06

9.  Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.

Authors:  Welf Prager
Journal:  Clin Pharmacol       Date:  2013-03-12

10.  Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study.

Authors:  Thomas Rappl; Daryousch Parvizi; Herwig Friedl; Maria Wiedner; Simone May; Bettina Kranzelbinder; Paul Wurzer; Bengt Hellbom
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.